Gil Awada (G Awada)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 14

Top Topics

Metastatic Colorectal Cancer

Peritoneal Dialysis

Dendritic Cells

Top Venues

Journal of clinical medicine

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Giuseppe Fasolino, Gil Awada, Laura Moschetta, Jorgos Socrates Koulalis, Bart Neyns, Bert Verhelst, Peter Van Elderen, Pieter Nelis, Paul Cardon de Lichtbuer, Wilfired Cools, Marcellinus Ten Tusscher
Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study. Journal of clinical medicine 12 (3) (2023)
Giuseppe Fasolino, Gil Awada, Laura Moschetta, Jorgos Socrates Koulalis, Bart Neyns, Bert Verhelst, Peter Van Elderen, Pieter Nelis, Paul Cardon de Lichtbuer, Wilfired Cools, Marcellinus Ten Tusscher
Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study. Journal of clinical medicine 12 (3) (2023)
Giuseppe Fasolino, Gil Awada, Laura Moschetta, Jorgos Socrates Koulalis, Bart Neyns, Bert Verhelst, Peter Van Elderen, Pieter Nelis, Paul Cardon de Lichtbuer, Wilfired Cools, Marcellinus Ten Tusscher
Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study. Journal of clinical medicine 12 (3) (2023)
Julia Katharina Schwarze, Soizic Garaud, Yanina J L Jansen, Gil Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, Bart Neyns
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. Cancers 14 (3) (2022)
Yanina Jeanne Leona Jansen, Astrid A M van der Veldt, Gil Awada, Bart Neyns
Anti-PD-1: When to Stop Treatment. Current oncology reports 24 (7) (2022)
Julia Katharina Schwarze, Jens Tijtgat, Gil Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns
Intratumoral administration of CD1c (BDCA-1) + and CD141 (BDCA-3) + myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. Journal for immunotherapy of cancer 10 (9) (2022)
Johnny Duerinck, Julia Katharina Schwarze, Gil Awada, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Laura Seynaeve, Louise Cras, Nicky D'Haene, Alex Michotte, Ben Caljon, Isabelle Salmon, Michaël Bruneau, Mark Kockx, Sonia Van Dooren, Anne-Marie Vanbinst, Hendrik Everaert, Ramses Forsyth, Bart Neyns
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial. Journal for immunotherapy of cancer 9 (6) (2022)
Gil Awada, Laila Ben Salama, Jennifer De Cremer, Julia Katharina Schwarze, Lydia Fischbuch, Laura Seynaeve, Stephanie Du Four, Anne-Marie Vanbinst, Alex Michotte, Hendrik Everaert, Anne Rogiers, Peter Theuns, Johnny Duerinck, Bart Neyns
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). Journal for immunotherapy of cancer 8 (2) (2021)
Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns
A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT). Cancers 13 (9) (2021)
Gil Awada, Yanina Jeanne Leona Jansen, Julia Katharina Schwarze, Jens Tijtgat, Lennert Hellinckx, Odrade Gondry, Sim Vermeulen, Sarah Warren, Kelly Schats, Pieter-Jan van Dam, Mark Kockx, Marleen Keyaerts, Hendrik Everaert, Teofila Seremet, Anne Rogiers, Bart Neyns
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. Cancers 13 (2) (2021)
Sim Vermeulen, Gil Awada, Marleen Keyaerts, Bart Neyns, Hendrik Everaert
Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome. Current oncology (Toronto, Ont.) 28 (3) (2021)
Yanina Jeanne Leona Jansen, Inneke Willekens, Teofila Seremet, Gil Awada, Julia Katharina Schwarze, Johan De Mey, Carola Brussaard, Bart Neyns
Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse. Cancers 13 (3) (2021)
Julia Katharina Schwarze, Gil Awada, Louise Cras, Jens Tijtgat, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, Bart Neyns
Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. Vaccines 8 (4) (2020)
Anne Rogiers, Christophe Leys, Justine Lauwyck, Adrian Schembri, Gil Awada, Julia Katharina Schwarze, Jennifer De Cremer, Peter Theuns, Paul Maruff, Mark De Ridder, Jan L Bernheim, Bart Neyns
Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab. Journal of immunology research 2020 (2020)